Reading ERNA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ERNA free→Reading ERNA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ERNA free→QuarterlyIQ Insights · ERNA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “ Company ”, “ we ”, “ us ”, or “ our ”), received a written notice (the “ Notice ”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Nasdaq staff (the “ Staff ”) determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per…
Entry into a Material Definitive Agreement. On February 6, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Brookline Capital Markets, a division of Arcadia Securities, LLC (the “Placement Agent”), pursuant to which the Company engaged the Placement Agent as the placement agent for the public offering (the “Offering”) of (i) 19,000,000 shares (the “Shares”) of the Company’s common stock, p…
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Former Independent Registered Public Accounting Firm On June 30, 2025, Ernexa Therapeutics Inc. (the “Company) dismissed Grant Thornton LLP (“Grant Thornton”) as the Company’s independent registered public accounting firm effective immediately. The Audit Committee of the Company’s Board of Directors (the “Board”) approved Grant Thornton’s dismissal on June 30, 2025. Grant Thornton performed audits of the Company’s consolidated fi…
Unregistered Sales of Equity Securities. The information in
Other Events. Completion of Second Closing of Private Placement As previously reported, on March 31, 2025, Ernexa Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) and a related registration rights agreement with certain accredited investors. Pursuant to the SPA, the Company agreed to issue and sell to the investors, and the investors agreed to purchase from the Company, in a private placement, an aggregate of 69,311,654 shares of common stock (or pre-…
Unregistered Sales of Equity Securities. The information in
Entry into a Material Definitive Agreement. On March 31, 2025, Ernexa Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “SPA”) with certain accredited investors and a related registration rights agreement (the “RRA”). Pursuant to the SPA, the Company agreed to issue and sell to the investors, and the investors agreed to purchase from the Company, in a private placement, an aggregate of 58,262,918 shares of common stock at a purchase price of $0.1046 per share…
Entry into a Material Definitive Agreement. On March 20, 2025, Eterna Therapeutics Inc. (the “Company”) issued a promissory note with an aggregate principal amount of $750,000 (the “Promissory Note”) to Charles Cherington. The Promissory Note accrues interest at a rate of 5.0% per annum, payable at maturity. Mr. Cherington owns approximately 32% of the Company’s outstanding shares of common stock and is also the holder of the Company’s outstanding promissory note in the amount of $1,500,000 i…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The description of the Promissory Note contained in
Entry into a Material Definitive Agreement. On March 11, 2025, Eterna Therapeutics Inc. (the “Company”) issued a promissory note with an aggregate principal amount of $1,500,000 (the “Promissory Note”) to Charles Cherington. The Promissory Note accrues interest at a rate of 5.0% per annum, payable at maturity. The Promissory Note matures on earliest of (a) June 15, 2025, (b) the first business day on which the Company has received aggregate proceeds of greater than $5 million in respect of th…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The description of the Promissory Note contained in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.